International classification of diseases (ICD) ICD 101 gives five diagnoses of gender identity disorders (GID) .
(1) Transsexualism .
This has three criteria: A desire to live and be accepted as a member of the opposite sex, usually accompanied by a sense of discomfort with, or inappropriateness of, one’s anatomic sex, and a wish to have surgery and hormonal treatment to make one’s body as congruent as possible with one’s preferred sex.The transsexual identity is present persistently for two years.
The disorder is not a symptom of another mental disorder or a chromosomal abnormality.
(2) Dual role transvestism
(3) GID of childhood
(4) Other GIDs
(5) GID, unspecified
According to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), a person must show strong persistant cross-gender identification (not merely a desire for any perceived cultural advantage of being the other sex) and a persistent discomfort with their sex or a sense of inappropriateness in the gender role of that sex, to be diagnosed with GID. The term transsexualism has been replaced with GID by DSM IV.
PREVALENCEStudies carried out in Netherlands (data collected from 1975 to 1992) quoted the prevalence of transsexualism as 1:11,900 in men and 1:30,400 in women.A study carried out in Scotland (1998) in primary care units estimated the prevalence of gender dysphoria (a subjective experience of incongruity between genital anatomy and gender identity) among patients aged over 15 years as 8.18 per 100,000, with an approximate sex ratio of 4:1 in favour of men.4 The interdepartmental working group on transsexual people published by the home office reported that 44 maleto- female operations and four female-to-male operations were performed in the National Health Service (NHS) and 104 gender reassignment operations performed in the private sector during 1997/1998. According to hospital episode statistics data 2004–05 (Department of Health, UK),
there were 338 finished hospital episodes of transsexualism (ICD 10 code F64.0) and 114 finished hospital episodes of operation for sexual transformation (OPCS 4 code X15), with 131 days of median waiting period (period of time between date of decision to admit and date of actual admission).6 It should be noted that this data relates to patient care in NHS only.
Strategies and Evidence
General Principles of Treatment
Professional acceptance of transsexualism and its hormonal and surgical treatment has grown. Interventions are indicated only after comprehensive psychological assessment has confirmed not only that the DSM diagnostic criteria have been fulfilled but also that the patient meets the criteria for readiness to make the transition to the other sex (as detailed below).Persons with gender identity disorder may have unrealistic expectations about what being a member of the opposite sex entails. Hormonal treatment should therefore be preceded and accompanied by an extended period (at least 1 year) during which the patient lives full time as a person of the desired sex. This real-life experience is essential for providing insight into the new sex status, allowing the patient to become accustomed to the social interactions arising from it. Such sex reassignment, by enabling the patient to experience life as a person of the subjectively appropriate sex, reduces gender dysphoria and improves social and sexual functioning.
Hormonal Sex Reassignment
The goals of hormonal treatment are to induce the development of the secondary sex characteristics of the new sex and to diminish those of the natal sex.Prior hormonal effects on the skeleton and vocal cords cannot be reversed. No randomized trials have been conducted to determine the optimal formulations and dosages of cross-sex hormones. Treatment strategies resemble those used for hypogonadal patients (see Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).Male-to-Female Transsexuals
Hormonal therapy is prescribed for male-to-female transsexuals to induce breast formation and a more female distribution of fat and to reduce male-pattern hair growth. To achieve these goals, the biologic action of androgens must be almost completely neutralized. Administration of estrogens suppresses gonadotropin output and therefore androgen production, but combining this treatment with a progestational agent, a gonadotropin-releasing-hormone (GnRH) analogue, or other medications that suppress androgen action (e.g., cyproterone acetate, flutamide, nilutamide, or bicalutamide) appears to be more effective.Many estrogens are available. Ethinyl estradiol, although efficacious, should be avoided. When taken at the dosages required for sex reassignment, this agent has been associated with significantly increased risks of venous thrombosis and death from cardiovascular causes, as compared with 17β-estradiol.
Although progestins suppress androgen production, they have no role in the feminization of the body and may have harmful metabolic effects; consequently, progestins should be discontinued after orchiectomy. In postmenopausal women, progestins combined with estrogens increase the risk of breast cancer. Men undergoing androgen-deprivation treatment for prostate cancer are at increased risk for features of the metabolic syndrome. Studies assessing the metabolic effects of androgen deprivation and estrogen therapy in male-to-female transsexuals have shown that increases in visceral fat are associated with increases in triglyceride levels, insulin resistance, and blood pressure. Available data from one large practice with a median follow-up of 18.5 years have not suggested an increased risk of death from cardiovascular causes with treatment except among current users of ethinyl estradiol. Data from larger and longer-term studies are not .
Female-to-Male Transsexuals
Treatment in female-to-male transsexuals is intended to induce virilization. This includes male-pattern hair growth, the development of male physical contours, and the cessation of uterine bleeding. The principal hormonal treatment is a testosterone preparation . Concomitant progestin therapy is nearly always needed when testosterone is administered transdermally, since serum testosterone levels are lower with transdermal administration than with intramuscular administration, lessening suppression of gonadotropins.Long-Term Treatment
After sex-reassignment surgery, including gonadectomy, hormonal therapy must be continued. Some male-to-female transsexuals continue to have male-pattern hair growth; continued administration of antiandrogens, typically at only about half the preoperative dose, reduces male-pattern hair growth. Continued administration of cross-sex hormones is required to avoid symptoms and signs of hormone deficiency, such as vasomotor symptoms and, in particular, osteoporosis. Observational studies have shown that bone mass is generally maintained with estrogen alone in male-to-female transsexuals and with testosterone alone in female-to-male transsexuals when prescribed at the doses typically used to treat hypogonadism. Sufficient intake of calcium and vitamin D is also recommended. A blood concentration of serum luteinizing hormone in the normal range is a reliable marker of adequate dosing. If sex-reassignment surgery has taken place, the usual prescribed dose of estradiol in male-to-female transsexuals is approximately 50 μg per day and that of testosterone in female to-male transsexuals is typically the same as that used preoperatively: 200 to 250 mg every 2 weeks in parenteral form or 5 to 10 g per day in gel form. lists the potential side effects of sex steroids and recommendations for monitoring.Risks and Contraindications
A serious concern regarding long-term administration of cross-sex hormones is the possibility of an increased risk of hormone-dependent cancers. There are rare case reports of prolactinomas, breast cancers, and prostate carcinomas in male-to-female transsexuals and rare reports of ovarian carcinoma, breast cancer, and vaginal cancer (one each of the latter two, to my knowledge) in female-to-male transsexuals. Rare cases of hormone-dependent tumors in organs other than the reproductive organs (e.g., lung, colon, and brain [meningioma]) have also been reported in transsexuals who have undergone estrogen treatment. Evidence is lacking to indicate a significantly increased frequency of cancers in association with cross-sex hormonal treatment, but the available data are from studies that involved relatively short-term exposure. Risks may become more apparent as subjects age and the duration of hormone exposure increases. Because a portion of administered testosterone is aromatized to estradiol, female-to-male transsexuals who have not undergone breast removal and oophorectomy–hysterectomy should be monitored for estrogen-sensitive cancers of the breast, endometrium, and ovaries.Although the addition of a progestin may help to prevent endometrial cancer, studies of postmenopausal hormone use suggest that this therapy may increase the risk of breast cancer.It has also been reported that testosterone may contribute to the development of breast and endometrial cancer; therefore, monitoring of female-to-male transsexuals for such cancers is also prudent. Transsexuals may not always be forthright with physicians about their sex change, and this hesitancy can lead to delays in diagnosing cancers of organs specific to the former sex.Surgical Sex Reassignment
Male-to-female sex reassignment involves the surgical construction of a neovagina, with the penile skin or colon usually used for vaginal lining and scrotal skin used for the labia. The breasts may be augmented if their development is judged to be insufficient. Masculine facial features and a prominent Adam's apple may also be surgically mitigated.Female-to-male sex reassignment should ideally include removal of the breasts, uterus, and ovaries because the development of cancer in these organs is not easily detected. In rare instances, the clitoris becomes sufficiently hypertrophied after testosterone exposure to serve as a phallus. Otherwise, the patient can undergo a metoidioplasty (see Figure 2 in the Supplementary Appendix), which involves elongation and reconstruction of the clitoris as a small neopenis with erectile function,sometimes allowing urination in a standing position. Free flaps of tissue removed from the arms or legs can be used to construct a neophallus. Procedures have been developed to provide rigidity for penetration, including insertion of autologous cartilage or bone, rigid implants, or an inflatable prosthesis, but these procedures, and their outcomes, remain cumbersome. A scrotum can be constructed from the labia majora along with implantation of a testicular prosthesis. The aesthetic results of surgery depend largely on surgical skill.
Surgical treatment improves the overall quality of life for most transsexual persons. However, 1 to 2% of those who have undergone surgical sex reassignment regret it, the majority being men with late-onset transsexuality. Determining eligibility for hormonal and surgical treatment is more complex with these patients than it is with those who have early-onset transsexuality. When regrets occur, they may reflect difficulties in making the transition to a different lifestyle because of appearance or limited social skills. These problems appear to be more common in patients with late-onset transsexuality, who have lived in their natal sex for a long time, underscoring the importance of actually living as the other sex before undergoing cross-sex surgery.
Juvenile Gender Dysphoria
Over the past two decades, awareness of gender identity disorder in children and adolescents has grown.Although most juveniles with gender identity disorder are otherwise psychologically healthy, certain forms of psychiatric conditions may be present (most commonly anxiety, mood, and disruptive disorders) and can complicate accurate diagnosis and assessment of eligibility for treatment. Gender identity disorder must be distinguished from conditions also associated with feelings of being different (e.g., extreme transvestic fetishism and autism spectrum disorders). As a rule, only extreme cases of gender identity disorder persist into adolescence and beyond. An experience of the first somatic signs of hormonal puberty as alienating is diagnostically significant and a marker that that the gender identity disorder will probably persist.If diagnostic criteria for gender identity disorder are met in adolescence, development of secondary sex characteristics may be suspended with the use of GnRH analogue treatment alone. This intervention is reversible and allows time for reflection on the desire to undergo sex reassignment while pubertal development is halted. Although correct diagnosis requires that the first signs of physical puberty be allowed to emerge, GnRH analogue administration should begin before it is too late to reverse the process. This is possible during stage B3 (breast bud extending beyond areola) in girls and during stage G3 (increase in testicular volume of ≥4 ml, with measurable nocturnal testosterone values) in boys. Once daytime testosterone production commences (testicular volume ≥10 ml), virilization becomes irreversible. For the duration of GnRH analogue administration, increases in bone mass cease, but there is typically no loss. The goal of treatment is the same as that for the treatment of precocious puberty — returning hormone levels to prepubertal levels.
GnRH analogues are expensive and progestins offer an alternative treatment that also suppresses gonadotropin secretion. In addition, the use of antiestrogens in girls and antiandrogens in boys delays the progression of puberty, although neither class of agents is as effective as GnRH analogues.
If the follow-up diagnostic process confirms the diagnosis of gender identity disorder and the well-being of the patient increases with the cessation of pubertal development, cross-sex hormones may be added in a stepwise fashion in accordance with the treatment protocols for hypogonadal children.The addition of cross-sex hormones usually begins at the age of legal medical competence (16 years of age in most Western countries). Parental agreement may be required, but even if it is not, parental support is of paramount importance. Follow-up should include anthropometric measurements, assessment of bone mineral density and metabolic measures (e.g., lipid and glucose levels and bone turnover), psychometric testing, and ongoing counseling.
Limited observational data from juvenile transsexuals have indicated that gender dysphoria is reduced and relationships and academic skills are improvedafter early treatment for sex reassignment. Beginning treatment at the time of puberty appears to be associated with better outcomes (e.g., in psychopathologic scores) than beginning in adulthood, by which time irreversible sex characteristics may pose lifelong barriers to successful sex reassignment.
Areas of Uncertainty
Although several studies have shown amelioration of gender dysphoria and improvements in social and sexual functioning in transsexuals who have undergone sex reassignment, none have conclusively demonstrated that medical interventions resolve gender dysphoria. Comparative studies are lacking to inform decision making regarding regimens and dosing of cross-sex hormones. Recommendations for management are based on expert opinion; studies of the efficacy and safety of hormone preparations are lacking, as are dose–response studies of sex hormone preparations. Large, long-term studies are needed to provide data on the long-term risk of disease, especially for cardiovascular disease and cancer, which are of particular concern in older patients and in those who have had prolonged exposure to sex hormones. Data are also needed on how the administration of GnRH analogues followed by cross-sex hormonal treatment affects pubertal development. Unresolved questions are whether there is an age at which cross-sex hormonal treatment should be discontinued and whether hormone replacement should be avoided in older male-to-female transsexuals.Guidelines from Professional Societies
Guidelines for the treatment of transsexuals have been formulated by the World Professional Association for Transgender Health and are published in its 2001 report, Standards of Care for Gender Identity Disorders. These guidelines have been elaborated, with a special focus on cross-sex hormones, in the most recent guidelines from the Endocrine Society The recommendations in this review are consistent with these guidelines.Conclusions and Recommendations
The person described in the vignette has gender dysphoria that is probably consistent with a diagnosis of gender identity disorder. The diagnosis must be verified by an experienced mental health professional, with attention to eligibility and readiness for sex reassignment. The patient needs to understand that sex reassignment brings relief of gender dysphoria only — other psychological problems may remain. Expectations about physical appearance and life after sex reassignment must also be realistic. Because real-life experience is indispensable, a prerequisite for surgical sex reassignment is at least a year of experience living entirely as a member of the new sex, with complete habituation to the new behaviors and to the responses of others. Patients who follow this procedure rarely have regrets after sex reassignment.Persons undergoing sex reassignment can be reassured that serious short-term complications of cross-sex hormonal treatment appear to be uncommon. However, longer-term effects on the risks of cardiovascular disease, metabolic disease, and cancer are not well charted.
Reference:
Care of Transsexual Persons http://www.nejm.org/doi/full/10.1056/NEJMcp1008161
Health Insurance Discrimination for Transgender People http://www.hrc.org/issues/9568.htm
Gender identity disorder: treatment and post-transition care in transsexual adults http://wiki.ubc.ca/images/f/f9/Article_1-Wik
No comments:
Post a Comment